ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Y-mAbs announces FDA clearance of IND for its Lutetium-177 labelled omburtamab antibody
October 21, 2020Y-mAbs Therapeutics announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug application for 177Lu-omburtamab-DTPA for the treatment of medulloblastoma, which is the most common type of primary brain cancer.. -
Endocyte and ITM Announce Long-Term Supply Agreement for No-Carrier-Added Lutetium-177
July 10, 2018WEST LAFAYETTE, Ind. & GARCHING, Germany--(BUSINESS WIRE)-- Endocyte, Inc. (Nasdaq:ECYT), and ITM Isotopen Technologien München AG (ITM)
Pharma Sources Insight January 2025
